1. Describe the clinical features of periocular infantile haemangioma. 2. Discuss a new tool that will determine the amblyopic risk and monitor treatment effects in the management of periocular haemangioma. 3. Assess the effects of propranolol in the treatment of periocular haemangioma, based on a case series.
Introduction
Haemangiomata of infancy are common benign lesions occurring in up to 10% of children in their first year. 1 When occurring periocularly, and left untreated, their visual sequelae are common. 1 Amblyopia is the primary concern because of stimulus deprivation, induced anisometropia (mainly oblique astigmatism), secondary strabismus, or globe displacement. 2 In 2008, Léauté-Labrèze et al 3 reported a serendipitous discovery in the treatment of capillary haemangioma with propranolol. Propranolol has since been increasingly adopted as a first-line treatment for haemangioma 4 and, while uncertainty of ideal dosage and treatment regimens still remains, 2 mg/kg/day split in three daily doses, is a frequently used regime. 4 There is no consensus in the literature on the optimum time to start or stop propranolol therapy.
In this paper, we develop an approach using two formulae to calculate the amblyogenic risk.
Materials and methods
This is a retrospective clinical study of the first nine children who underwent propranolol treatment in our institution between 2009 and 2013 for periocular haemangioma.
Patients were started on 2 mg/kg/day propranolol by the paediatric team as per a local protocol. The cycloplegic refraction of both eyes was measured periodically. The initiation of treatment is based on the perceived risk of amblyopia from anisometropia, rather than observed difference in visual acuity.
To calculate an amblyogenic risk, the difference between the two refractions (from each eye) is calculated and expressed as a third theoretical refraction, using the Retzlaff formula. 5 This is done by taking vector components of the cylinders in both the horizontal and vertical planes and comparing them. The formula accounts for the spherical equivalent, astigmatic power, and axis. It therefore will account for hypermetopic and myopic refractions, as well as positive and negative cylinder format. A calculation is then applied to this product, as described by Holladay et al 6 to produce a single dioptre value, which Holladay termed the delta defocus equivalent (DFE), which might represent the amblyopic risk (as the DFE is proportional to the reduced visual acuity induced by that refraction 6 ). Where the normal eye had an oblique refraction opposite to the affected eye, this was reflected about the 901 axis before being incorporated in the equation. As this is applied to the difference between the two refractions, we have termed this DFE-q. A Microsoft Excel (Microsoft, Redmond, WA, USA) spreadsheet was used to implement DFE-q calculation. 7 The following information was subsequently extracted from the patient files: lesion location, lesion typesuperficial (lid) or deep (orbit), visual axis occlusion, age at initiation and termination of treatment, refractions, and visual acuity measured when treatment was discontinued (termed end visual acuity).
Results
Nine cases of periocular capillary haemangioma were treated in this study. None of the children had occlusion of the visual axis. The average DFE-q at commencement of propranolol was 1.54 ( ± 0.62) D. The average at the end of treatment was 0.39 ( ± 0.38) D (Table 1) . Figure 1 shows the DFE-q over the period of treatment for all the nine participants. It also demonstrates the DFE-q trend in patient I prior to initiating propranolol treatment.
Of note is the DFE-q rise corresponding to rebound haemangioma growth in patient E whose propranolol treatment was stopped prematurely. Patient E's initial response to propranolol is represented by a drop from 2.54 to 1.06 after 9 weeks of treatment. After 20 weeks, the propranolol was tapered down as his mother had concerns that the treatment was contributing to breathholding attacks. Refraction measurements were not taken at 20 weeks; however, the DFE-q calculations at 31 weeks (2.14 D) and 36 weeks (2.5 D) correlate to the clinically observed re-bound growth. At 36 weeks, 2 mg/kg/day propranolol was re-started and the DFE-q began to fall once more ending at 1.20 D.
Discussion
This work demonstrates a useful application of the Retzlaff formula and DFE as a tool for assessing amblyopic risk and monitoring treatment effect in infantile haemangioma management.
Measurement of the treatment effect from propranolol varies widely in the literature. Qualitative approaches have included the use of visual analogue scales to assess the lesion with respect to its colour, size and growth. 8 Imaging with ultrasound, MRI 9 , and photographic surface area measurement 10 have also been used. Ophthalmic quantitative measurements have mainly focused on calculating an amblyogenic astigmatic error from the difference in cylinder power between the affected and unaffected eyes. [10] [11] [12] Where cylinder axis and spherical equivalent are similar, the proposed formula for calculating the amblyogenic risk will have little advantage. However, this will ignore oblique axes induced by the haemangioma (eg patients A, B, and F) as well as over playing the cylinder power significance if the spherical equivalent is similar (eg patient D). We suggest a DFE-q calculation ultimately will be more accurate as all components of the refraction are included; however, we accept cylinder power alone will act as a guide. Larger studies will be needed to compare the two.
The decision to begin propranolol treatment was always made clinically; however, our results suggest a DFE-q of 1.5 D could be an appropriate guide, particularly if it is increasing over time, in support of the treatment decision.
This clinical study also adds to the increasing body of evidence 4 in support of propranolol as a first-line treatment for periocular haemangioma.
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3.
According to the case series by Burne and Taylor, which of the following statements about the effects of propranolol in treatment of periocular haemangioma would most likely be correct?
A Propranolol is used only as second-line treatment of haemangioma. B
The ideal dosage regimen is 1 mg/kg/day, split into two daily doses. C The average DFE-q at initiation of propranolol was 1.54 ( ± 0.62) D, and the average at treatment completion was 0.39 ( ± 0.38) D. D There was no evidence of rebound haemangioma growth when propranolol treatment was stopped prematurely. 
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